Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Imaging, Diagnosis, Prognosis

Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer

Zhennan Gu, Mark A. Rubin, Yu Yang, Samuel E. Deprimo, Hongjuan Zhao, Steven Horvath, James D. Brooks, Massimo Loda and Robert E. Reiter
Zhennan Gu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Rubin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel E. Deprimo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongjuan Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Horvath
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Brooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Loda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert E. Reiter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-04-0356 Published March 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The diagnosis and management of prostate cancer is hampered by the absence of markers capable of identifying patients with metastatic disease. In order to identify potential new markers for prostate cancer, we compared gene expression signatures of matched androgen-dependent and hormone refractory prostate cancer xenografts. One candidate gene overexpressed in a hormone refractory xenograft was homologous to the regenerating protein gene family, a group of secreted proteins expressed in the gastrointestinal tract and overexpressed in inflammatory bowel disease and cancer. This gene, Reg IV, was confirmed to be differentially expressed in the LAPC-9 hormone refractory xenograft. Consistent with its up-regulation in a hormone refractory xenograft, it is expressed in several prostate tumors after neoadjuvant hormone ablation therapy. As predicted by its sequence homology, it is secreted from transiently transfected cells. It is also expressed strongly in a majority of hormone refractory metastases represented on two high-density tissue microarrays. In comparison, it is not expressed by any normal prostate specimens and only at low levels in ∼40% of primary tumors. These data support Reg IV as a candidate marker for hormone refractory metastatic prostate cancer.

  • Prostate cancer
  • secreted
  • marker
  • Reg IV

INTRODUCTION

Prostate cancer is the most common malignancy and the second leading cause of cancer-related death in American men. Prostate cancer is a biologically and clinically heterogeneous disease. A majority of men with this malignancy harbor slow-growing tumors that may not impact an individual's natural life span, although others are struck by rapidly progressive, metastatic tumors. Prostate-specific antigen screening is limited by a lack of specificity and an inability to predict which patients are at risk to develop hormone refractory metastatic disease. Recent studies advocating a lower prostate-specific antigen threshold for diagnosis may increase the number of prostate cancer diagnoses and further complicate the identification of patients with indolent versus aggressive cancers (1). New serum and tissue markers that correlate with clinical outcome or identify patients with potentially aggressive disease are urgently needed (2).

Recent expression profiling studies suggest that expression signatures for metastatic versus nonmetastatic tumors may reside in the primary tumor (2–4). Additional features that predispose tumors to metastasize to specific organs may also be present at some frequency in the primary tumor (5). These recent observations suggest that novel markers of premetastatic or prehormone refractory prostate cancer may be identified in early stage disease. These markers may also play a role in the biology of metastatic or hormone refractory prostate cancer progression. Recent examples of genes present in primary tumors that correlate with outcome and play a role in the biology of prostate cancer progression include EZH2 and LIM kinase (6, 7). However, neither of these two genes is secreted.

In order to identify new candidate serum or tissue markers of hormone refractory prostate cancer, we compared gene expression profiles of paired hormone-dependent and hormone refractory prostate cancer xenografts. The LAPC-9 xenograft was established from an osteoblastic bone metastasis and progresses from androgen dependence to independence following castration in immunodeficient mice (8). It has been used previously to identify candidate therapeutic targets in prostate cancer. Differentially expressed genes were validated and then examined for sequence homology to secreted or cell surface proteins. We report here on the identification, characterization, and initial validation of one such candidate gene, Reg IV, a new member of the regenerating family of secreted C-lectin proteins (9). Reg proteins are normally expressed in the gastrointestinal tract and are induced in inflammatory bowel disease and some gastrointestinal malignancies. Their pleiotropic functions include promoting tissue regeneration, proliferation, and resistance to apoptosis (10). We show that Reg IV encodes a secreted protein, which is not expressed in the normal prostate. Reg IV is expressed at low levels in a subset of primary tumors and is moderately or highly expressed in a majority of hormone refractory and metastatic tumors. These results suggest that Reg IV may be a potential marker of prostate cancer metastasis or hormone refractory growth.

MATERIALS AND METHODS

Microarray Analysis of Gene Expression. Tumor samples from a matched pair of androgen-dependent and -independent LAPC-9 xenografts were grown and prepared as described previously (8). Total RNA was isolated by using Ultraspec RNA isolation systems (Biotecx). mRNA was purified using Oligotex mRNA Midi Kit (Qiagen). Two micrograms of mRNA was reverse-transcribed, and cDNA was then labeled with Cy-5. Labeled tumor cDNA was combined with a Cy-3-labeled common reference RNA derived from 11 different cell lines and hybridized to cDNA microarrays containing 22,648 elements representing 17,083 genes, as reported previously (11). The slides were scanned with a GenePix microarray scanner (Axon Instruments) and were analyzed with Genepix software. Spots of insufficient quality were excluded from analysis by visual inspection. Data files were entered into the Stanford Microarray Database, where spot intensity was correlated with gene identification. Only features with a signal intensity >50% above background in either Cy5 or Cy3 channel and whose expression varied at least 4-fold between the paired samples were retrieved from the Stanford Microarray Database. Detailed descriptions of array manufacture, hybridization protocols, and data analysis are available at http://cmgm.Stanford.EDU/pbrown.

Construction of myc-His-Tagged Reg IV Expression Vector. The Reg IV coding sequence was subcloned into the multiple cloning site of pcDNA3.1/myc-His expression vector (Invitrogen) at the BamHI and EcoRI sites. The reading frame was confirmed by sequencing.

RNA Probes and In situ Hybridization. A 399 bp DNA fragment from the 3′-untranslated region of Reg IV (Genbank AI732541) was inserted into the pCR2.1 vector (Invitrogen) in both sense and antisense orientations under the control of the T7 promoter. Plasmids were linearized and digoxigenin-labeled riboprobes were generated using the DIG RNA Labeling Kit (Roche Applied Science). Automated in situ hybridization was done on the Discovery System (Ventana Medical Systems, Tucson, AZ). After deparaffinization, slides were soaked in 2× SSC for 5 minutes and digested with proteinase K (Life Technologies, at a final concentration of 10 μg/mL) for 30 minutes at 37°C. Sense and antisense riboprobes were diluted at 1:100 (1 μg of probe/mL) in hybridization solution (50% deionized formamide, 10% polyethylene glycol, 0.3 mol/L NaCl, 10 mmol Tris (pH 8.0), 1 mmol EDTA, Denhardt's solution 1×, yeast tRNA 500 μg/mL, 50 mmol DTT). The hybridization was done for 6 hours at 65°C with 100 μL of hybridization solution. After hybridization, slides were washed twice at 70°C for 6 minutes in 1.0× SSC. The hybridization was followed by a 30-minute incubation with a biotinylated anti-digoxigenin (Sigma BioSciences, St. Louis, MO), followed by alkaline phosphatase–conjugated streptavidin for 16 minutes. Visualization procedure was done in nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Ventana mapBlue) for 5 hours and finally in hematoxylin counterstain.

Recombinant Reg IV Expression and Immunoprecipitation. 293T cells were transiently transfected with a myc-his tagged Reg IV expression vector by calcium phosphate precipitation for 48 hours. Cell labeling and immunoprecipitation was done as described (12). Briefly, cells were labeled with 500 μCi of trans-35S label (ICN) in methionine and lysine-free DMEM (Invitrogen) containing 5% of dialyzed fetal bovine serum for 4 hours. Cell lysates and conditioned medium were incubated with 3 μg of anti-myc monoclonal antibody (9E10), and 20 mL of protein G-Sepharose CL-4B (Amersham) for 2 hours at 4°C. Samples were washed and boiled in SDS sample buffer for 5 minutes and separated on 12.5% SDS-PAGE. The gel was treated with Amplify (Amersham) before being dried and autoradiographed.

Northern Blot Analysis of Gene Expression. RNAs were extracted as described above. Ten micrograms of RNA was separated on a 1.2% agarose denaturing gel, transferred to nitrocellulose filters, and hybridized with RT-PCR-prepared DNA fragments of Reg IV (Genbank AI732541). Probes were labeled with α 32PdCTP by random priming using the random primer labeling system (Amersham) and hybridization was carried out at 62°C in 6× SSC overnight, followed by washing with 2× SSC-0.1% SDS and 0.2× SSC-0.1% SDS at 62°C. For multiple tissue Northern analysis, the hybridization was done as described by the manufacturer (Clontech).

Case Selection for Tissue Microarray. In order to evaluate Reg IV, we used a prostate cancer progression tissue microarray. This tissue microarray is composed of benign prostate tissue, localized prostate cancer, and hormone refractory metastatic prostate cancer. These cases came from well-fixed radical prostatectomy specimens from the University of Michigan (Ann Arbor, MI), the University Hospital Ulm (Ulm, Germany), and the rapid autopsy program from the University of Michigan Specialized Program of Research Excellence in Prostate Cancer (13). All samples were collected with prior Institutional Review Board approval at each respective institution. This tissue microarray was composed of classic acinar prostate cancers and areas demonstrating foamy gland features from the same cases. Benign tissue samples were also placed in the tissue microarray to serve as a negative control. A second array containing predominantly metastatic cases was also stained and scored.

Scoring of Reg IV Expression. Reg IV expression was determined using a validated scoring method (7, 14–16) where staining was evaluated for intensity. Benign epithelial glands and prostate cancer cells were scored for Reg IV staining intensity on a four-tiered system ranging from negative to strong expression. A score of 1 was negative, a score of 2 was considered low expression, a score of 3 indicated moderate expression, and a score of 4 correlated with strong expression. Slides were read independently by two pathologists (M. Rubin and M. Loda) with >90% interobserver agreement.

Construction and Production of Lentivirus Expressing Reg IV-Myc.His. A Myc.His-tagged Reg IV construct was PCR-amplified from a pcDNA Reg IV-myc.his vector and inserted into the lentiviral vector chemokine/chemokine receptor through restriction sites of EcoRI and NheI (17). Lentivirus stocks were generated by calcium phosphate mediated transfection of 293T cells. The titer of the virus was checked with 293T cells using chemokine/chemokine receptor-enhanced green fluorescent protein as a positive control and indicator.

LNCaP and LAPC-9 Prostate Xenograft Models. LNCaP or LNCaP-Reg IV.myc.his cells (5 × 106) were mixed with an equal volume of Matrigel and inoculated into severe combined immunodeficiency mice s.c. In the case of LAPC-9, explanted tumor is digested with Pronase and cultured in 10% fetal bovine serum-RPMI 1640 for 16 hours. Cells are then transduced by chemokine/chemokine receptor lentivirus alone or lentivirus RegIV.myc.mis at a multiplicity of infection of 5 for 2 hours. Cells are then washed with culture media, mixed with Matrigel, and inoculated back to severe combined immunodeficiency mice (1 × 106 cells/mice).

ELISA Detection of Serum RegIV.myc.his. Twenty-five microliters of mouse serum was mixed with 75 mL of PBS and incubated in Ni-NTA HisSorb strips (Qiagen) for 3 hours. The strips were washed with PBS-0.1% Tween 20 and then incubated with 1:5,000 diluted anti-Myc monoclonal antibody (Invitrogen) for 45 minutes. The 1:10,000 diluted anti-mouse IgG antibodies conjugated with alkaline phosphatase (Promega) were then incubated for 45 minutes. After washing, the color was developed using one-step nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Pierce) for 20 minutes and read at 450 nm.

Statistics. The Pearson χ2 statistic was used to test whether the rows (e.g., tumor type) and columns (e.g., Reg expression) of a table were independent. To test for differences of Reg expression across different tumor types, we also used the Kruskal-Wallis test, which is a nonparametric multigroup comparison tests. Statistical analyses were done using the freely available R software (http://www.r-project.org).

RESULTS

Cloning and Characterization of Reg IV. The LAPC-9 xenograft was established from metastatic prostate tumors and progresses in vivo from androgen dependence to independence. In order to identify novel candidate markers of prostate cancer progression, RNAs from paired androgen-dependent and androgen-independent LAPC-9 tumors were labeled and hybridized to 24,000 spot cDNA arrays with common reference RNA. Two hundred and four clones representing 101 named genes and 59 expressed sequences tags showed expression variation of at least 4-fold between the androgen-dependent and androgen-independent samples. Out of the 101 named genes, 75 have been characterized functionally to some degree and most can be categorized into six biological processes according to Gene Ontology annotations: cell-cell signaling/signal transduction, cell adhesion/motility, structural molecule/cytoskeleton, immune response, cell proliferation/cell cycle, and metabolism (Table 1). Eleven androgen-responsive genes, including well-known androgen targets such as klk3 (prostate-specific antigen), were identified by comparison to the expression profiles of 567 androgen-regulated transcripts we had identified previously (Table 1). With one exception (WWP1), all of the genes normally up-regulated by androgens showed decreased expression in the androgen-independent tumor growing in the castrated animal, confirming that androgens modulate their expression in vivo.

View this table:
  • View inline
  • View popup
Table 1

Genes highly differentially expressed in LAPC-9 androgen-dependent and androgen-independent tumors

We focused our attention on uncharacterized genes that were differentially expressed between the androgen-dependent and androgen-independent samples. Two of the most highly up-regulated transcripts in the androgen-independent tumor have extensive homology to the Reg family of secreted C-type lectins, a family of proteins normally expressed in the upper gastrointestinal tract and believed to play important roles in response to tissue injury, islet cell regeneration, and tumorigenesis. On Northern blot, a single 1.2 kb band was present in multiple independently derived hormone refractory LAPC-9 tumors, but not in the paired parental androgen-dependent LAPC-9 tumors or other xenografts (Fig. 1A). The microarray result was also confirmed by quantitative PCR, which showed an average 70-fold increase in expression of these expressed sequences tags in androgen-independent LAPC-9 tumors compared with androgen-dependent ones (data not shown). These results show that two expressed sequences tags related to the Reg gene family are reproducibly up-regulated during androgen-independent progression of LAPC-9.

Fig. 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1

Reg IV expression in prostate cancer xenografts and in normal tissues and Reg IV secretion. Northern analysis of Reg IV in prostate xenografts (A), showing overexpression in two hormone refractory (androgen-independent) sublines of LAPC-9, and multiple normal tissues (B), with notable expression in the colon. Expression was also seen in pancreas and small bowel in a multiple tissue dot blot (not shown here). C, myc-tagged Reg IV cDNA was transiently transfected into 293 T cells and recovered from the conditioned media with an anti-Myc antibody. A control antibody did not identify this band, indicating that it is Reg IV. Likewise, a Myc antibody did not pull down a specific protein from a vector-only transfectant control (data not shown).

A full-length cDNA was obtained by 5′ and 3′ rapid amplification of cDNA ends PCR, sequenced, and found to be identical to Reg IV, a newly described member of the Reg gene family. Reg IV has an open reading frame of 474 bp, predicting a peptide of 158 amino acids with an NH2-terminal signal sequence of 22 amino acids. It is 39% similar to Reg I and Reg III, the other two members of this gene family in humans (9).

A multiple tissue Northern blot was probed and showed that Reg IV expression is restricted to the gastrointestinal tract, most prominently the colon (Fig. 1B). Expression was also seen in pancreas and small intestine (duodenum and jejunum) on a 76-tissue dot blot, suggesting that there may be interindividual variations in the level and location of Reg IV expression (data not shown). No expression was seen in prostate on either blot. Digital Northern analysis using the Cancer Genome Anatomy Project (NIH) database confirmed this normal tissue distribution, and also showed that Reg IV expressed sequences tags were present in several prostate, gastric, and colon cancers (UniGene cluster Hs. 105484), suggesting that Reg IV expression may be expressed more broadly in prostate cancer and not limited to LAPC-9.

Reg IV Encodes a Secreted Protein of ∼20 kDa and Is Detectable in Serum of Tumor-Bearing Animals. Reg IV is predicted to be a secreted protein based on the presence of a putative signal sequence and on its homology to Reg I and III (9). To confirm this prediction, we transiently expressed a myc-tagged Reg IV cDNA construct in 293T cells and harvested the cell pellets and conditioned media. As shown in Fig. 1C, the majority of Reg IV protein was found in the culture medium, consistent with the conclusion that Reg IV is a secreted protein. A single band of ∼20 kDa was identified, again consistent with the predicted molecular weight of Reg IV.

In order to determine if secreted Reg IV can be detected in the serum of prostate cancer-bearing mice, LNCaP and LAPC-9 prostate cancer cells were stably transduced with lentivirus constructs expressing myc.his-tagged human Reg IV. Expression of tagged Reg IV was confirmed by Western blot and then tumors were established s.c. in severe combined immunodeficiency mice. Non-Reg IV expressing tumors were also established as controls. Once tumors reached an average size of 1 cm, serum was obtained and the mice were sacrificed. An ELISA assay was developed to detect the presence of the myc.his-tagged protein as described in MATERIALS AND METHODS. Control sera were used to normalize for background signal. The sera from animals containing his.myc.Reg IV-positive LNCaP and LAPC-9 tumors were positive, whereas all control animals were negative (ELISA data not shown). These results suggest that Reg IV is secreted and that it is released into and is detectable in serum.

Reg IV Is Expressed by High-Risk Tumors Treated with Neoadjuvant Hormone Ablation Therapy. Reg IV was identified in hormone refractory LAPC-9 sublines, suggesting that Reg IV might be involved in hormone refractory prostate cancer progression. In order to test this hypothesis preliminarily, sense and antisense Reg IV probes were generated and hybridized to four radical prostatectomy specimens obtained from patients with high-risk (high grade and locally advanced) tumors treated with neoadjuvant hormone ablation therapy for 3 to 8 months. All four cases had residual disease, which stained specifically with the antisense Reg IV probe, but not the control sense probe. No staining was seen in residual adjacent normal tissue (Fig. 2A). These results show that Reg IV is expressed in residual hormone refractory prostate cancer. The pretreatment sample for these patients was not available to test the hypothesis that Reg IV expression was induced by androgen ablation.

Fig. 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2

In situ expression analysis of Reg IV expression. A, the antisense probe (right) shows Reg IV (brown) expression in an androgen-independent tumor but not in the adjacent normal tissue to the left of the tumor. The sense control (left), is negative; B, progression of Reg IV expression. Top left (a) is normal prostate, which is not staining; top right (b), negative Gleason 6 cancer; bottom left (c) is a Gleason 9/10 primary tumor staining strongly for Reg IV (note intense purple color); bottom right (d), strongly staining lymph node metastasis.

To determine if Reg IV expression is androgen-regulated, LAPC-4 and LNCaP cell lines were grown in the absence of androgen and assayed for Reg IV expression. No Reg IV induction was seen after androgen starvation in tissue culture or in hormone refractory variants of these cell lines in vivo (Fig. 1A), suggesting that the Reg IV expression seen in hormone refractory LAPC-9 tumors and in tumors treated with neoadjuvant hormone ablation is not regulated simply by the removal of androgen.

Reg IV Is Strongly Expressed by a Majority of Metastatic Prostate Cancers. In order to study Reg IV expression further, a tissue array spanning the gamut of prostate histology (n = 211 tissue microarray elements) was evaluated by RNA in situ hybridization (Fig. 2B). The percentage of samples staining positive for Reg IV increased from benign to clinically localized to metastatic prostate cancer. None of the 48 evaluable benign specimens expressed Reg IV, whereas 44.6% (25/56) of primary tumors and 62.5% (40/64) of metastatic tumors stained positively (Table 2). These differences (between normal and primary tumors, and between primary tumors and metastases) were statistically significant (P = 0.00000038 and one-sided P = 0.038, respectively) and show that the prevalence of Reg IV expression increases as prostate cancers progress.

View this table:
  • View inline
  • View popup
Table 2

Distribution of Reg IV expression on a prostate cancer tissue array

We also evaluated the relative level of Reg IV expression in benign, localized, and metastatic tumors. As shown in Fig. 3, the overall intensity of Reg IV staining increased from benign to clinically localized to metastatic prostate cancer, with a median staining intensity of 1.0, 1.7, and 2.5, respectively (Kruskal-Wallis test; P < 0.001; note that a score of 1 means no detectable expression). Whereas a majority of positive localized tumors expressed only weak levels of Reg IV, a majority of positive metastatic tumors stained strongly (Table 2). The increase in Reg IV staining intensity between benign prostate tissue and localized prostate cancer was statistically significant (P = 0.00000016). Likewise, metastatic prostate cancer had statistically higher expression of Reg IV than localized prostate cancer (Kruskal-Wallis test; P < 0.00033). These differences show that the level of Reg IV expression increases as prostate cancers progress, particularly in metastatic cancer.

Fig. 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3

Reg IV expression in normal, primary, and metastatic prostate cancer. The mean expression score ± SD for Reg IV expression is shown for normal prostate, primary prostate cancer, and metastatic prostate cancer. The results summarize a prostate cancer tissue array representing the gamut of prostate tissues.

We also asked whether Reg IV expression is associated with tumor grade in localized tumors. As shown in Fig. 4, Reg IV expression was significantly more intense among high grade tumors (i.e., Gleason 7-10) than in low grade ones (i.e., Gleason 5-6; Mann-Whitney test, P = 0.03). There was no association of Reg IV expression with recurrence or survival.

Fig. 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4

Association of Reg IV expression with Gleason score. The mean expression score ± SD for Reg IV expression is shown for Gleason 5-6 and 7-10 prostate tumors.

To confirm the high-intensity expression in metastatic prostate cancer, we also evaluated an array containing 259 metastases obtained from 24 patients who died of hormone-refractory metastatic prostate cancer. The mean staining intensity in autopsy cases was 3.2, similar to that in the “progression” array. Benign prostate tissue on this array was negative. Among positive tumors, almost all cells stained positive, again similar to the progression array. These results confirm that as prostate cancer progresses, there is increasing expression of Reg IV. Expression is highest in hormone refractory metastatic tumors.

DISCUSSION

The two seminal events in the natural history of prostate cancer are metastasis and progression to androgen independence. The ability to predict at diagnosis the clinical course of an individual tumor is currently suboptimal. Thirty percent of clinically localized tumors recur after local therapy and a subset of these go on to metastasize and kill their host. The association of Reg IV expression with androgen independence and metastasis raises the possibility that expression of Reg IV may correlate with the risk of progression to hormone refractory metastasis. Expression of the Reg IV homologues Reg 1α and PAP has been reported to predict for reduced survival from colon cancer (10). Indeed, we found that increasing Reg IV expression did correlate with higher grade primary tumors, suggesting that Reg IV expression may have prognostic utility in primary tumors. However, there was no association with recurrence in this initial small series. Analysis of Reg IV expression in a larger patient cohort with long-term follow-up will be necessary to determine its relationship to recurrence and prostate cancer survival. None of the patients with localized tumors in our database went on to die from prostate cancer.

Because Reg IV is secreted, it might also be useful as a serum marker to identify patients with metastasis or at risk to develop metastases. This possibility is supported by the ability to detect Reg IV in the serum of tumor-bearing animals. Antibodies against Reg IV are currently being generated to assess Reg IV protein expression in tissue samples and to measure circulating Reg IV levels in normal and cancer patients. An important issue will be to determine if Reg IV expression in the gastrointestinal tract interferes with the detection of Reg IV from tumor tissue.

Reg IV was cloned from a hormone refractory xenograft and is expressed by both androgen-resistant local tumors and metastases. It is not known whether Reg IV expression is related specifically to androgen independence and/or metastasis because all of the metastases were obtained from hormone refractory patients. Reg IV expression does not seem to be regulated by androgen, because androgen starvation of both LAPC-4 and LNCaP prostate cancer cell lines in tissue culture did not result in Reg IV expression. Nor did androgen-independent sublines of LNCaP or LAPC-4 express Reg IV in vivo. Additional studies will be needed to understand the regulation of Reg IV in prostate cancer.

The biological role of Reg IV in prostate cancer progression is not known. Reg proteins have been associated with proliferation and regeneration, cell survival, resistance to apoptosis, and cell adhesion. Hartupee et al. (9) reported that Reg IV is highly expressed in ulcerative colitis and hypothesized that it might be related to the high rate of colon cancer in individuals with this disease. Violette et al. (18) found a consistent relationship between Reg IV expression and chemotherapy resistance in colon cancer cell lines. They found that Reg IV is expressed in five of seven chemoresistant lines, but is absent from all chemosensitive lines. Importantly, they noted that Reg IV is expressed by LS513, a cell line that survives but does not proliferate in the presence of chemotherapy, suggesting that Reg IV may be a survival factor rather than a mitogen. Similarly, recent studies have shown that Reg Iα is a signaling intermediate in a survival pathway in motoneurons (19). The hypothesis that Reg IV might play a role in cell survival is consistent with its expression in hormone-refractory prostate cancer. The association of Reg IV expression with chemotherapy resistance is also consistent with the fact that a majority of patients with lethal prostate cancer metastases on our tissue array received chemotherapy during their clinical course.

Reg IV is the second gastrointestinal secreted protein that we have identified in prostate cancer. Intestinal trefoil factor (ITF/TFF3) was initially identified in prostate cancer arrays and has since been reported to be expressed by ∼40% of localized prostate cancers and a higher percentage of metastases (20–22). Trefoil factors are known to play an important role in intestinal protection and restitution, a process in which mucosal continuity is re-established following tissue injury, whereas Reg proteins are believed to play a role in tissue regeneration (23). Both Reg and trefoil proteins are overexpressed in inflammatory bowel disease. Both are also overexpressed in malignancy. TFF3, for example, is an adverse prognostic factor in gastric cancer (23). It will be important to understand the reasons why several related gastrointestinal proteins are expressed in prostate cancer, their regulation and their functions as paracrine or autocrine factors. Reg IV, TFF3, and their receptors (a receptor for Reg 1 was recently identified) might also be useful therapeutic targets for the management of prostate cancer (24).

Footnotes

  • Grant support: Department of Defense grant PC 001588 and American Cancer Society grant (R. Reiter).

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted November 19, 2004.
    • Received February 24, 2004.
    • Revision received October 26, 2004.

References

  1. ↵
    Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335–42.
    OpenUrlCrossRefPubMed
  2. ↵
    Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410–5.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49–54.
    OpenUrlCrossRefPubMed
  4. ↵
    Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393–8.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537–49.
    OpenUrlCrossRefPubMed
  6. ↵
    Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U S A 2003;100:7247–52.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624–9.
    OpenUrlCrossRefPubMed
  8. ↵
    Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999;59:5030–6.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Hartupee JC, Zhang H, Bonaldo MF, Soares MB, Dieckgraefe BK. Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochim Biophys Acta 2001;1518:287–93.
    OpenUrlPubMed
  10. ↵
    Macadam RC, Sarela AI, Farmery SM, Robinson PA, Markham AF, Guillou PJ. Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer 2000;83:188–95.
    OpenUrlCrossRefPubMed
  11. ↵
    Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999;303:179–205.
    OpenUrlCrossRefPubMed
  12. ↵
    Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998;95:1735–40.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Rubin MA, Putzi M, Mucci N, et al. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038–45.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Rubin MA, Zhou M, Dhanasekaran SM, et al. α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662–70.
    OpenUrlCrossRefPubMed
  15. ↵
    Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822–6.
    OpenUrlCrossRefPubMed
  16. ↵
    Kuefer R, Varambally S, Zhou M, et al. α-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002;161:841–8.
    OpenUrlPubMed
  17. ↵
    Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, Osborne WR. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 2001;12:1103–8.
    OpenUrlCrossRefPubMed
  18. ↵
    Violette S, Festor E, Pandrea-Vasile I, et al. Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer 2003;103:185–93.
    OpenUrlCrossRefPubMed
  19. ↵
    Nishimune H, Vasseur S, Wiese S, et al. Reg-2 is a motoneuron neurotrophic factor and a signalling intermediate in the CNTF survival pathway. Nat Cell Biol 2000;2:906–14.
    OpenUrlCrossRefPubMed
  20. ↵
    Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683–8.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Garraway IP, Seligson D, Said J, Horvath S, Reiter RE. Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 2004;61:209–14.
    OpenUrlCrossRefPubMed
  22. ↵
    Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004;61:215–27.
    OpenUrlCrossRefPubMed
  23. ↵
    Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003;4:721–32.
    OpenUrlCrossRefPubMed
  24. ↵
    Kobayashi S, Akiyama T, Nata K, et al. Identification of a receptor for reg (regenerating gene) protein, a pancreatic β-cell regeneration factor. J Biol Chem 2000;275:10723–6.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 11 (6)
March 2005
Volume 11, Issue 6
  • Table of Contents
  • About the Cover
  • Index by Author

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer
Zhennan Gu, Mark A. Rubin, Yu Yang, Samuel E. Deprimo, Hongjuan Zhao, Steven Horvath, James D. Brooks, Massimo Loda and Robert E. Reiter
Clin Cancer Res March 15 2005 (11) (6) 2237-2243; DOI: 10.1158/1078-0432.CCR-04-0356

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer
Zhennan Gu, Mark A. Rubin, Yu Yang, Samuel E. Deprimo, Hongjuan Zhao, Steven Horvath, James D. Brooks, Massimo Loda and Robert E. Reiter
Clin Cancer Res March 15 2005 (11) (6) 2237-2243; DOI: 10.1158/1078-0432.CCR-04-0356
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TP53 in Breast Cancer
  • FDOPA PET Survival Predictions for Glioma
  • In vivo Fluorescence Lifetime Imaging for Monitoring the Cancer Treatment
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement